Trafficking of CAR T cells to sites of subclinical leukaemia cutis

Lancet Oncol. 2020 Mar;21(3):e179. doi: 10.1016/S1470-2045(19)30861-7.

Authors

Maeve O'Reilly¹, Claire Roddie², Maria A V Marzolini², Manuel Rodriguez-Justo³, Sabine Pomplun³, Martin Pule², Karl S Peggs²

Affiliations

¹ Department of Haematology, University College London Cancer Institute, London, UK. Electronic address: maeve.o'[email protected].
² Department of Haematology, University College London Cancer Institute, London, UK.
³ Department of Histopathology, University College London Cancer Institute, London, UK.

PMID: 32135121
DOI: 10.1016/S1470-2045(19)30861-7

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19 / immunology*
Cell Movement*
Humans
Immunotherapy, Adoptive*
Leukemic Infiltration*
Male
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Chimeric Antigen / genetics
Receptors, Chimeric Antigen / immunology*
Recurrence
Skin / immunology*
Skin / pathology
Treatment Outcome

Substances

Antigens, CD19
CD19 molecule, human
Receptors, Chimeric Antigen

Associated data

ClinicalTrials.gov/NCT02893189